Sequel Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://sequelpharma.com
Effects of Intravenous K201 on the Restoration of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Sequel Pharmaceuticals, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT01259622
Phase 2 Study of Oral K201 for Prevention of AF Recurrence
Phase 2
Terminated
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: K201 TabletDrug: Placebo Tablet
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Sequel Pharmaceuticals, Inc
- Target Recruit Count
- 300
- Registration Number
- NCT01067833
Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: K201 Injection
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2010-01-08
- Lead Sponsor
- Sequel Pharmaceuticals, Inc
- Target Recruit Count
- 153
- Registration Number
- NCT00626652
© Copyright 2025. All Rights Reserved by MedPath